ChronoScale Corporation Common Stock (NASDAQ:CHRN) Sees Large Growth in Short Interest

ChronoScale Corporation Common Stock (NASDAQ:CHRN) was the target of a large increase in short interest in the month of May. As of May 15th, there was short interest totaling 424,399 shares, an increase of 135.1% from the April 30th total of 180,534 shares. Approximately 12.8% of the shares of the company are short sold. Based on an average daily trading volume, of 420,857 shares, the days-to-cover ratio is currently 1.0 days.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of ChronoScale Corporation Common Stock in a report on Friday, March 27th. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Reduce” and an average price target of $6.00.

ChronoScale Corporation Common Stock Price Performance

NASDAQ CHRN traded down $1.36 during trading hours on Monday, reaching $17.00. The company’s stock had a trading volume of 234,471 shares, compared to its average volume of 206,723. The firm has a market capitalization of $60.52 million, a price-to-earnings ratio of -3.16 and a beta of 1.02. ChronoScale Corporation Common Stock has a 1-year low of $2.73 and a 1-year high of $20.70. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.55 and a quick ratio of 1.03. The company’s 50-day moving average is $12.34 and its two-hundred day moving average is $9.41.

ChronoScale Corporation Common Stock (NASDAQ:CHRN) last released its quarterly earnings results on Tuesday, April 28th. The company reported ($2.04) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.03) by ($2.01). ChronoScale Corporation Common Stock had a negative return on equity of 197.81% and a negative net margin of 135.66%.The business had revenue of $2.14 million during the quarter, compared to analyst estimates of $4.29 million. On average, equities analysts predict that ChronoScale Corporation Common Stock will post -0.1 EPS for the current year.

Institutional Investors Weigh In On ChronoScale Corporation Common Stock

Large investors have recently bought and sold shares of the company. Roble Belko & Company Inc increased its stake in ChronoScale Corporation Common Stock by 104.5% during the 1st quarter. Roble Belko & Company Inc now owns 2,338 shares of the company’s stock worth $25,000 after buying an additional 1,195 shares in the last quarter. Virtu Financial LLC purchased a new stake in ChronoScale Corporation Common Stock during the 3rd quarter worth approximately $57,000. Shay Capital LLC purchased a new stake in ChronoScale Corporation Common Stock during the 3rd quarter worth approximately $67,000. Citadel Advisors LLC purchased a new stake in ChronoScale Corporation Common Stock during the 3rd quarter worth approximately $198,000. Finally, Geode Capital Management LLC increased its stake in ChronoScale Corporation Common Stock by 68.9% during the 4th quarter. Geode Capital Management LLC now owns 25,212 shares of the company’s stock worth $218,000 after buying an additional 10,281 shares in the last quarter. 6.42% of the stock is currently owned by hedge funds and other institutional investors.

ChronoScale Corporation Common Stock Company Profile

Ekso Bionics Holdings, Inc (NASDAQ:EKSO) is a leading developer of wearable bionic exoskeletons designed to enhance human mobility and strength. Headquartered in Richmond, California, the company was founded in 2005 (originally as Berkeley Bionics) and completed its initial public offering in 2014. Its patented robotic systems support both rehabilitation and industrial applications by providing powered, adjustable assistance for a range of movement tasks.

In the medical sector, Ekso Bionics offers externally worn exoskeletons such as the EksoNR and EksoGT, which assist patients recovering from stroke, spinal cord injury or other neurological conditions.